PAUL GORDON
Engineers in Chicago, IL

4735934, Apr 5, 1988

Oct 27, 1986

6/923205

Paul Gordon - Chicago IL

Greenwich Pharmaceuticals Incorporated - Greenwich CT

A61K 3170

514 25

The invention provides a method of therapeutically treating a warm blooded animal afflicted with an autoimmune disease such as rheumatoid arthritis. In one variant, this is accomplished by administering an ethereally monosubstituted monosaccharide having the general formula M. sub. 1 --O--Y, and/or an ethereal monosubstitution of monosaccharide derivatives having the general formula M. sub. 2 --O--Y, and/or pharmaceutically acceptable organic acid and inorganic acid salts thereof as defined hereinafter. In a preferred variant, a synergistic mixture is used containing one or more of the foregoing compounds as a first ingredient and an additional compatible substance as a second ingredient which is effective to therapeutically treat autoimmune diseases in warm blooded animals. The invention further provides a novel synergistic composition for therapeutically treating warm blooded animals afflicted with an autoimmune disease which consists essentially of the aforementioned first and second ingredients.

3939145, Feb 17, 1976

Mar 1, 1973

5/337134

Paul Gordon - Chicago IL

Strategic Medical Research Corporation - Chicago IL

C07H 506

260210R

The invention provides a novel therapeutic composition comprising a pharmaceutically acceptable carrier containing a therapeutically effective amount of an ethereally monosubstituted monosaccharide having the general formula S-O-Y, wherein S is the residue of a monosaccharide selected from the group consisting of pentoses, hexoses and heptoses and Y is selected from the group consisting of cyclic monovalent nitrogen containing organic radicals and residua and monovalent organic radicals and residua having the general formula ##EQU1## wherein R. sub. 1 is a divalent organic radical having a linear carbon chain length of about 1-7 carbon atoms and R. sub. 2 and R. sub. 3 are selected from the group consisting of --H, --OH, --SH, halogen and monovalent organic radicals and residua having a linear carbon chain length of about 1-7 carbon atoms. The invention also provides certain novel ethereally monosubstituted monosaccharides, of which 3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucose is an example. The novel monosaccharides show striking antiviral activity or other therapeutically valuable properties and are useful as an active ingredient in the above therapeutic composition.

RE33000, Jul 25, 1989

Mar 18, 1983

6/474737

Paul Gordon - Chicago IL

Greenwich Pharmaceuticals, Incorporated - Greenwich CT

A61K 3170, C12P 500, C07H 506

514 25

The invention provides a novel therapeutic composition comprising a pharmaceutically acceptable carrier containing a therapeutically effective amount of an ethereal monosubstitution of a monosaccharide derivative having the general formula S-O-Y, wherein S is the residue of the monosaccharide derivative selected from the group consisting of pentoses, hexoses and heptoses as single or polysubstituted acetals, ketals or esters and Y is selected from the group consisting of cyclic monovalent nitrogen-containing organic radicals and residua and monovalent organic radicals and residua having the general formula ##STR1## wherein R. sub. 1 is a divalent organic radical having a linear carbon chain length of about 1-7 carbon atoms and R. sub. 2 and R. sub. 3 are selected from the group consisting of --H, --OH, --SH; halogen and monovalent organic radicals and residua having a linear carbon chain length of about 1-7 carbon atoms. The invention also provides certain novel ethereal monosubstitutions of monosaccharide derivatives, of which 3-O-3'-(N',N'-dimethylamino-n-propyl)-1,2-O-isopropylidene-D-glucofuranose is an example.

4016261, Apr 5, 1977

Sep 2, 1975

5/609723

Paul Gordon - Chicago IL

Strategic Medical Research Corporation - Murray UT

A61K 3170

424180

The invention provides a novel therapeutic composition comprising a pharmaceutically acceptable carrier containing a therapeutically effective amount of an ethereally monosubstituted monosaccharide having the general formula S--O--Y, wherein S is the residue of a monosaccharide selected from the group consisting of pentoses, hexoses and heptoses and Y is selected from the group consisting of cyclic monovalent nitrogen containing organic radicals and residua and monovalent organic radicals and residua having the general formula ##STR1## wherein R. sub. 1 is a divalent organic radical having a linear carbon chain length of about 1-7 carbon atoms and R. sub. 2 and R. sub. 3 are selected from the group consisting of --H, --OH, --SH, halogen and monovalent organic radicals and residua having a linear carbon chain length of about 1-7 carbon atoms. The invention also provides certain novel ethereally monosubstituted monosaccharides, of which 3--O--3'-(N',N'-dimethylamino-n-propyl)-D-glucose is an example. The novel monosaccharides show striking antiviral activity or other therapeutically valuable properties and are useful as an active ingredient in the above therapeutic composition.

5095104, Mar 10, 1992

Aug 3, 1990

7/563103

Paul Gordon - Chicago IL

C07G 300, C07H 1302, C07H 1504, C07H 2300

536 41

A glucofuranose derivative substituted at the 3,5,6- or 3,6-positions with a radical that provides an anionic charge at physiological pH values is disclosed, as are pharmaceutical compositions, and methods of making and using the same. The compounds are useful in treating inflammation, and particularly conditions that involve neutrophil influx; they are also useful in inhibiting peptic ulcer formation.

5358936, Oct 25, 1994

Jul 31, 1991

7/738597

Paul Gordon - Chicago IL
Edward P. Gamson - Highland Park IL

A61K 3170, C07H 1302, C07H 1504, C07H 2300

514 25

A glucofuranose derivative substituted at the 3,5,6- or 3,6-positions with a radical that provides an anionic charge at physiological pH values is disclosed, as are pharmaceutical compositions, and methods of making and using the same. The compounds are useful in treating inflammation, and particularly conditions that involve neutrophil influx; they are also useful in inhibiting gastric ulcer formation.